Expres2ion Biotech Holding AB (EXPRS2) Stock Overview

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase III clinical trial. It also develops influenza, breast cancer, and malaria vaccines. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. Further, it sells ExpreS2 test kits and reagents for application as research tools or diagnostics. It has a collaboration agreement with Evaxion Biotech A/S for the development of a novel cytomegalovirus (CMV) vaccine candidate. The company operates an online store. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.